Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n
Action and use<\/strong><\/p>\n Dopamine receptor antagonist; neuroleptic.<\/p>\n Fluanisone is 4\u2032-fluoro-4-[4-(2-methoxyphenyl)piperazin-1-yl]-butyrophenone. It contains not less than 98.0% and not more than 101.0% of C21H25FN2O2, calculated with reference to the dried substance.<\/p>\n White or almost white to buff-coloured crystals or powder; odourless or almost odourless. It exhibits polymorphism.<\/p>\n Practically insoluble in water; freely soluble in chloroform, in ethanol (96%), in ether and in dilute solutions of organic acids.<\/p>\n A. The infrared absorption spectrum, Appendix II A, is concordant with the reference spectrum of fluanisone\u00a0 (RSV 22). If the spectra are not concordant, dissolve 0.1 g of the substance being examined in 3 ml of dichloromethane and evaporate the solvent at room temperature, scratching the side of the container occasionally with a glass rod and prepare a new spectrum of the residue.<\/p>\n B. The light absorption, Appendix II B, in the range 230 to 350 nm of a 0.002% w\/v solution in a mixture of 9 volumes of propan-2-ol and 1 volume of 0.1M hydrochloric acid exhibits a well-defined maximum only at 243 nm. The absorbance at 243 nm is about 1.1.<\/p>\n C. Heat 0.5 ml of chromic-sulphuric acid mixture in a small test tube in a water bath for 5 minutes; the solution wets the side of the tube readily and there is no greasiness. Add 2 to 3 mg of the substance being examined and again heat in a water bath for 5 minutes; the solution does not wet the side of the tube and does not pour easily from the tube.<\/p>\n 72\u00b0 to 76\u00b0, Appendix V A.<\/p>\n Carry out the method for thin-layer chromatography, Appendix III A, using the following solutions.<\/p>\n (1) 2.0% w\/v of the substance being examined.<\/p>\n (2) 0.010% w\/v of the substance being examined.<\/p>\n (3) 0.020% w\/v of 4\u2032-fluoro-4-chlorobutyrophenone BPCRS.<\/p>\n (4) 0.010% w\/v of 1-(2-methoxyphenyl)piperazine BPCRS.<\/p>\n (a) Use as the coating silica gel GF254 precoated plate (Merck silica gel 60 plates are suitable).<\/p>\n (b) Use the mobile phase as described below.<\/p>\n (c) Apply 10 \u00b5l of each solution.<\/p>\n (d) Develop the plate to 15 cm.<\/p>\n (e) After removal of the plate, dry in air and expose to iodine vapour for 15 minutes.<\/p>\n 10 volumes of ethanol (96%) and 90 volumes of chloroform.<\/p>\n In the chromatogram obtained with solution (1):<\/p>\n any spots corresponding to 4\u2032-fluoro-4-chlorobutyrophenone and 1-(2-methoxyphenyl)piperazine are not more intense than the spots in the chromatograms obtained with solutions (3) and (4) respectively (1% and 0.5%, respectively);<\/p>\n any other secondary spot in the chromatogram obtained with solution (1) is not more intense than the spot in the chromatogram obtained with solution (2) (0.5%).<\/p>\n Loss on drying<\/strong><\/p>\n When dried to constant weight at 40\u00b0 at a pressure not exceeding 0.7 kPa, loses not more than 0.5% of its weight. Use 1 g.<\/p>\n Sulphated ash<\/strong><\/p>\n Not more than 0.1%, Appendix IX A.<\/p>\n Carry out Method I for non-aqueous titration, Appendix VIII A, using 0.15 g and crystal violet solution as indicator. Each ml of 0.1M perchloric acid VS is equivalent to 17.82 mg of C21<\/sub>H25<\/sub>FN2<\/sub>O2<\/sub>.<\/p>\n Fluanisone should be protected from light.<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Dopamine receptor antagonist; neuroleptic. DEFINITION Fluanisone is 4\u2032-fluoro-4-[4-(2-methoxyphenyl)piperazin-1-yl]-butyrophenone. It contains not less than 98.0% and not more than 101.0% of C21H25FN2O2, calculated with reference to the dried substance. CHARACTERISTICS White or almost white to buff-coloured crystals or powder; odourless or almost odourless. It exhibits polymorphism….<\/p>\n","protected":false},"author":5,"featured_media":23990,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[176],"tags":[],"class_list":["post-23989","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-british-pharmacopoeia-veterinary-2020"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/23989","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=23989"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/23989\/revisions"}],"predecessor-version":[{"id":23993,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/23989\/revisions\/23993"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/23990"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=23989"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=23989"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=23989"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}DEFINITION<\/h2>\n
CHARACTERISTICS<\/h2>\n
IDENTIFICATION<\/h2>\n
TESTS<\/h2>\n
Melting point<\/h3>\n
Related substances<\/h3>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
MOBILE PHASE<\/h4>\n
LIMITS<\/h4>\n
ASSAY<\/h2>\n
STORAGE<\/h2>\n